π
|
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
20 auth.
R. C. Coombes,
P. Badman,
J. Lozano-Kuehne,
X. Liu,
I. Macpherson,
Ishtiaq Zubairi,
R. Baird,
N. Rosenfeld,
J. GarcΓa-Corbacho,
N. Cresti,
...
R. Plummer,
A. Armstrong,
R. Allerton,
D. Landers,
H. Nicholas,
L. McLellan,
A. Lim,
F. Mouliere,
O. Pardo,
M. Seckl
|
5 |
2022 |
5 π
|
π
|
RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).
16 auth.
M. Seckl,
P. Badman,
Xinxue Liu,
I. Macpherson,
Ishtiaq Zubairi,
R. Baird,
J. GarcΓa-Corbacho,
N. Cresti,
E. Plummer,
A. Armstrong,
...
R. Allerton,
D. Landers,
H. Nicholas,
L. McLellan,
A. Lim,
C. Coombes
|
4 |
2017 |
4 π
|
π
|
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
14 auth.
T. Evans,
E. Dean,
L. R. Molife,
Juanita Lopez,
M. Ranson,
F. El-Khouly,
Ishtiaq Zubairi,
C. Savulsky,
L. Reyderman,
Yan Jia,
...
L. Sweeting,
A. Greystoke,
J. Barriuso,
R. Kristeleit
|
3 |
2019 |
3 π
|
π
|
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
12 auth.
C. Twelves,
A. Anthoney,
C. Savulsky,
M. Guo,
L. Reyderman,
N. Cresti,
...
V. Semiglazov,
C. Timcheva,
Ishtiaq Zubairi,
R. Morrison,
R. Plummer,
T. Evans
|
1 |
2019 |
1 π
|
π
|
Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.
20 auth.
Juanita Lopez,
T. Evans,
E. Plummer,
N. Diamantis,
H. Shaw,
Ishtiaq Zubairi,
N. Haris,
J. MacDonald,
A. Greystoke,
R. Roux,
...
N. Tunariu,
L. R. Molife,
A. Hannah,
S. Anderson,
H. Lane,
M. Maurer,
A. Schmitt-Hoffmann,
F. Bachmann,
M. Engelhardt,
R. Kristeleit
|
1 |
2016 |
1 π
|
π¦
|
Case Discussion: A 63-year-old Male with Bilateral Adrenal Mass and Large Renal Cell Carcinoma: The Case for Chemotherapy.
Ishtiaq Zubairi,
Robert J. Jones
|
0 |
2016 |
0 π¦
|